Bigomet

Quick links to important sections

Bigomet

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Bigomet

Understanding Bigomet

Bigomet is an oral medication primarily utilized in the management of type 2 diabetes. It belongs to a class of drugs known as biguanides, which are designed to help control blood sugar levels in individuals whose bodies do not use insulin normally.

Mechanism of Action

The medication works through several distinct pathways to assist the body in maintaining glycemic balance:

  • Reduction of Glucose Production: It decreases the amount of glucose (sugar) produced and released by the liver.
  • Improved Insulin Sensitivity: It enhances the body's response to insulin, allowing cells to utilize existing blood sugar more effectively.
  • Absorption Delay: It slows the absorption of glucose from the intestines during the digestion of food.

Clinical Application

Bigomet is used specifically for type 2 diabetes, a condition where the body either produces insufficient insulin or has developed a resistance to the insulin it produces. It is often used as a foundational component of a broader management plan that includes specific dietary considerations and physical activity. Unlike some other diabetes medications, biguanides generally do not cause the body to produce more insulin, which reduces the likelihood of blood sugar levels dropping too low when used as a standalone treatment.

Regulatory References

  1. Metformin - StatPearls - NCBI Bookshelf

What side effects are possible with Bigomet?

Possible side effects and safety information

Metformin Hydrochloride (Bigomet) has a defined safety profile categorized by regulatory authorities, with most reactions affecting the digestive system.

Classification System-Organ Class Specific Reactions (Regulatory Terminology)
Very Common (ge 1/10) Gastrointestinal Disorders Diarrhea, nausea, vomiting, abdominal pain, loss of appetite
Common (ge 1/100 to < 1/10) Nervous System Disorders Taste disturbance (dysgeusia, metallic taste)
Very Rare (< 1/10,000) Metabolism and Nutrition Disorders Lactic Acidosis, Vitamin B12 deficiency

Serious Adverse Reaction: The most serious, but Very Rare, adverse reaction documented in the regulatory label is Lactic Acidosis. This is a life-threatening metabolic complication that can occur when metformin accumulates in the body.

Population-Specific Safety Considerations: The risk of Lactic Acidosis necessitates specific safety limitations related to organ function. The medication is officially contraindicated in patients with severe renal impairment (estimated glomerular filtration rate, or eGFR, below 30 mL/min/1.73 m^2) and in individuals with hepatic impairment or liver disease.

Time- or Duration-Related Safety Patterns: Gastrointestinal side effects are most frequently observed at the start of treatment and during dose escalation. Decreased Vitamin B12 absorption and serum levels are a documented potential consequence of long-term exposure.

Safety-Related Restrictions: The official safety profile requires temporary discontinuation during procedures involving iodinated contrast agents. It also lists conditions associated with tissue hypoxia (e.g., unstable congestive heart failure) and excessive alcohol intake as contraindications due to increased risk factors for Lactic Acidosis.

Overdose and Emergency Response

Overdose and when to seek help

The primary and most severe risk associated with an overdose or drug accumulation of Bigomet (Metformin) is the onset of Lactic Acidosis, a rare but life-threatening metabolic emergency documented in regulatory warnings, including the FDA’s Boxed Warning.

Overdose Risk and Manifestation Official Regulatory Statement
Documented Symptoms Overdose often presents with nonspecific symptoms such as malaise, muscle pain, increasing drowsiness, or generalized abdominal distress. Laboratory findings include low blood pH and elevated lactate levels.
Severe Clinical Signs Progressed cases may involve acidotic dyspnea (deep and rapid breathing), hypothermia, hypotension (low blood pressure), potentially leading to coma or cardiovascular collapse.
When to Seek Urgent Help The medication must be immediately discontinued and immediate medical attention or emergency treatment (hospitalization immediately) must be sought upon the first signs of these symptoms.
Key Risk Factors The risk of Lactic Acidosis is significantly increased by underlying conditions, including renal impairment, hepatic insufficiency, or the presence of excessive alcohol intake or dehydration.
Antidote and Treatment No specific antidote is known. The official management involves prompt hospitalization, continuous monitoring of metabolic status, and the use of hemodialysis to efficiently clear the accumulated drug and correct the severe acidosis.

The regulatory profile defines this condition as a critical trigger, requiring urgent medical intervention to manage the severe metabolic derangement.

Therapeutic Uses of Bigomet

What Bigomet Treats: Main Uses and Benefits

Bigomet (Metformin) is commonly used as a foundational therapeutic agent for the long-term management of Type 2 diabetes mellitus. Its application is focused on supporting the management of the condition’s core metabolic manifestations, and the medicine is indicated as an adjunct to diet and exercise to improve glycemic control in patients with T2DM.


The medication is relevant for addressing chronic hyperglycemia, which is applied across domains where additional symptomatic support is needed. It helps patients achieve effective glycemic control by supporting the stability of both fasting and postprandial (after-meal) sugar readings, which is a primary symptomatic domain.

The use is common in clinical scenarios where symptoms are related to systemic imbalance, assisting with the management of long-term health markers such as Glycated Hemoglobin (HbA1c). It is also applied in conditions characterized by insulin resistance, meaning the body's response to its own insulin is impaired. The drug supports the body's utilization of its own insulin, which contributes to improved comfort and stability in managing chronic sugar imbalances.

“This medication is applied in settings where symptoms become more noticeable and supportive sugar management is appropriate.”

Quick Fact: Relief for Chronic Hyperglycemia

Bigomet is generally used as a first-line intervention when diet and lifestyle adjustments alone are insufficient, often serving as long-term maintenance therapy and is relevant for supporting the patient’s stability during periods of chronic sugar imbalance.

Eligibility and Restrictions for Use

Eligibility Scope

The use of Bigomet (Metformin) is formally permitted for adults and for pediatric patients ge 10 years of age with Type 2 Diabetes Mellitus (immediate-release formulation). Eligibility is strictly governed by a patient’s renal function and metabolic status, as defined in regulatory documentation.


Official Contraindications and Restrictions

Category Official Regulatory Classification
Populations Contraindicated Severe renal impairment (estimated glomerular filtration rate, eGFR < 30 mL/min/1.73 m^2). Acute or chronic metabolic acidosis (including diabetic ketoacidosis). Known hypersensitivity to Metformin.
Conditional Discontinuation Use must be temporarily discontinued for procedures involving intravascular iodinated contrast agents or major surgical procedures.
Use Not Recommended Initiation of therapy is not recommended in patients with an eGFR between 30 and 45 mL/min/1.73 m^2. Use should generally be avoided in patients with hepatic impairment.
Pregnancy/Lactation Pregnancy: Use is generally based on benefit-risk assessment due to the medicine crossing the placenta. Lactation: Excreted into human milk in low amounts; the decision requires consideration of the drug’s importance to the mother.

The eligibility profile is conditional upon a patient's kidney function, which requires more frequent assessment in older adults (ge 65 years). Use is restricted by any condition associated with a high risk of lactic acidosis, such as acute heart failure or severe infection.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents describe interactions with Bigomet (Metformin Hydrochloride) primarily through its effect on renal elimination and its pharmacodynamic action on blood glucose.

Documented Interaction Patterns

Interaction Type Interacting Substance/Class Official Regulatory Statement
Renal Transporter Inhibition OCT2 Inhibitors (e.g., Cimetidine, Dolutegravir, Ranolazine) These agents decrease the renal clearance of Metformin, which officially leads to an increased systemic exposure and plasma concentration.
Timing-Based Restriction Iodinated Contrast Media Metformin must be temporarily discontinued before or at the time of the procedure and withheld for 48 hours afterward until renal function is confirmed as normal.
Pharmacodynamic Additive Effect Other Antidiabetic Agents (e.g., Insulin, Sulfonylureas) Co-administration may increase the risk of hypoglycemia due to additive glucose-lowering effects.
Pharmacodynamic Opposing Effect Glucocorticoids, Thiazide Diuretics These agents may reduce the glucose-lowering efficacy of Metformin due to their intrinsic hyperglycaemic activity.

Other Specific Interaction Constraints

Acute Alcohol Intoxication is classified as a combination not recommended due to a significantly elevated risk of Metformin-associated lactic acidosis. The risk of accumulation and interaction-related complications is also heightened in the elderly population and those with documented reduced renal function (e.g., eGFR < 45 mL/min/1.73 m2), as Metformin is cleared unchanged by the kidneys. Food co-administration is documented to affect the absorption profile of both immediate-release and extended-release tablets.

Mechanism of Action

The action of Metformin Hydrochloride is primarily defined by the targeted modulation of cellular energy pathways, resulting in alterations in glucose metabolism across two key physiological domains: the liver and peripheral tissues.

Core Action: Reduction of Hepatic Glucose Output

The molecule acts by partially inhibiting the Mitochondrial Complex I, which mediates a change in the cellular energy state, leading to the activation of the central energy sensor, AMPK (Adenosine Monophosphate-Activated Protein Kinase). This mechanism mediates a reduction in the rate of hepatic glucose synthesis and release, which is a key contributor to the overall systemic decrease in circulating glucose concentration.

⬆️ Enhancing Peripheral Glucose Utilization

This secondary domain describes how the drug increases the responsiveness of muscle and fat cells to existing insulin. The activation of AMPK promotes the movement of glucose transporters (GLUT4) to the surface of these peripheral cells, promoting glucose transport from the circulation. This action contributes to the systemic modulation of glucose homeostasis by facilitating the uptake and utilization of circulating glucose by peripheral tissues.

Dosage and Administration Information

How to Use Bigomet: Administration Guidelines

Bigomet (metformin hydrochloride) is administered exclusively via the oral route as a tablet. The administration principles follow established protocols and are dependent on the tablet formulation.


Dosing and Administration Frequency

Administration Detail Immediate-Release (IR) Tablets Modified/Extended-Release (SR/XR) Tablets
Starting Dose Typically 500 mg two times daily or 850 mg once daily. Typically 500 mg to 1000 mg once daily.
Maximum Daily Dose Up to 2550 mg in divided doses. Up to 2000 mg once daily.
Frequency Two to three times daily. Once daily.

Dosage is not static; it is gradually increased from the starting dose based on an individual's metabolic measurements and tolerability. This titration process typically involves dose increases in increments of 500 mg every week or two until the appropriate maintenance level is reached.


Procedural Administration Constraints

The timing of intake is critical: all formulations must be taken with or immediately after meals. The extended-release form is usually taken with the evening meal. For the modified-release tablets, it is essential that they are swallowed whole and must not be crushed, cut, or chewed, as this alters the intended drug release pattern.

Administration also depends on kidney function. Before starting Bigomet, and periodically thereafter, renal function (eGFR) must be assessed. Established clinical guidelines indicate specific dose modifications are necessary for certain levels of renal impairment, and use is restricted below a specific eGFR threshold. Furthermore, the medication must be temporarily stopped prior to certain surgical procedures or when receiving intravascular iodinated contrast agents, and it is resumed only after renal function stability is confirmed. Bigomet is intended for long-term management.

Recent Clinical Evidence

Recent Clinical Evidence Overview

This section summarizes the key research evidence that has evaluated the benefit of the metformin and glimepiride combination treatment for Type 2 Diabetes Mellitus (T2DM).


Efficacy in Glycemic Control

Clinical trials have investigated the fixed-dose combination (FDC) therapy, which pairs metformin (a biguanide) with glimepiride (a sulfonylurea). Studies have consistently evaluated the treatment's impact on key markers of blood sugar control.

  • HbA1c Reduction: Trial data, including those from randomized studies, have shown that participants initiating therapy with the glimepiride/metformin combination exhibited a notable reduction in mean Glycated Hemoglobin ( HbA1c) levels. For instance, in one study, the mean HbA1c level was observed to decrease significantly over a 3-month period.
  • Fasting and Postprandial Glucose: Findings also indicated that the combination treatment was associated with a decrease in both Fasting Plasma Glucose (FPG) and Postprandial Glucose (PPG) levels. This suggests an effect on both baseline and meal-related blood sugar readings.

Comparative and Long-Term Findings

Research has explored the use of the FDC in various patient scenarios:

  • Comparison to Monotherapy: Head-to-head comparisons have demonstrated that the combination therapy often achieved a greater reduction in HbA1c levels compared to using either metformin or glimepiride as monotherapy.
  • Fixed vs. Free Combination: Some trials have evaluated the fixed-dose combination (FDC) against the free combination (taking the two drugs separately). Results suggested that the fixed combination was generally comparable in effectiveness for lowering HbA1c.
  • Sub-Groups: The combination has been evaluated across diverse patient sub-groups, including those newly diagnosed with T2DM and those requiring additional therapy after initial failure of monotherapy.

Key Studies & References

  1. Efficacy and Safety Comparison of Metformin/Glimepiride Combination Versus Each Compound Alone in New Diagnosed Type 2 Diabetes Patients (RECOMMEND) - NCT01459809
  2. Comparative efficacy of glimepiride and metformin in monotherapy of type 2 diabetes mellitus: meta-analysis of randomized controlled trials
  3. AACE Releases 2023 Comprehensive T2 Diabetes Management Algorithm

Frequently Asked Questions (FAQ)

Common questions about Bigomet (FAQ)


Q: Can Bigomet cause weight changes?

Regulatory documents state that loss of appetite is listed as a very common side effect when starting the active ingredient. Additionally, weight loss is noted as a less common side effect associated with the medication in some patients.


Q: Do studies suggest Bigomet is used for conditions other than blood sugar management?

The officially approved purpose for Bigomet is the management of Type 2 Diabetes Mellitus. However, government health resources note that the active ingredient has been the subject of research for its potential influence on other health conditions, though Type 2 Diabetes is the official indication.


Q: Is Bigomet the same as Metformin?

Bigomet is a brand name for a medicine containing the active ingredient metformin hydrochloride. Metformin hydrochloride is the generic drug that belongs to the biguanide class.


Q: Why do some people feel stomach discomfort when they first start Bigomet?

Digestive side effects, such as stomach discomfort, diarrhea, and nausea, are listed as very common in official product information. These effects are documented to occur most frequently at the start of treatment and during any dose adjustment period.


Q: Can Bigomet affect my vitamin B12 levels?

Yes, official regulatory warnings state that decreased absorption and low serum levels of Vitamin B12 are a documented potential consequence of long-term exposure to the active ingredient. Regular monitoring of B12 and blood parameters may be required.


Q: Can older adults use Bigomet without special precautions?

Regulatory guidance advises that the initial and maintenance dose should be conservative in older adults. Furthermore, a patient's renal function (kidney function) must be assessed more frequently in this population due to a higher inherent risk of serious side effects.


Q: What kind of monitoring is done while a person is on Bigomet?

Official documents require that renal function (eGFR) be assessed before starting Bigomet and regularly thereafter. Due to potential effects, hematological parameters and Vitamin B12 levels should also be measured periodically.


Q: Does Bigomet cause low blood sugar (hypoglycemia)?

When used alone (monotherapy), the active ingredient is noted to carry a low risk of hypoglycemia (low blood sugar). However, when Bigomet is co-administered with other antidiabetic agents, such as insulin or sulfonylureas, the risk of hypoglycemia increases due to combined effects.


Q: Can Bigomet make people feel tired or fatigued?

Asthenia (lack of energy) is listed as a common side effect in official product information. Severe unusual sleepiness or malaise is also noted as a potential symptom of the rare but serious side effect known as Lactic Acidosis.


Q: Are there any differences between Bigomet and similar medicines in its class?

Bigomet's active ingredient belongs to the Biguanide class, which is distinguished from other antidiabetic drugs (like sulfonylureas). Its mechanism helps lower blood sugar primarily by acting on the liver and peripheral tissues, without forcing the pancreas to produce more insulin.


Q: What kind of patient eligibility criteria are described in official documents for Bigomet?

The active ingredient is formally indicated for people with Type 2 Diabetes Mellitus (adults and children ge 10 years) and is strictly contraindicated in patients with severe renal impairment or acute or chronic metabolic acidosis.


Q: How does Bigomet affect the liver?

Official regulatory guidance advises against use or initiation of therapy in patients with hepatic impairment (liver disease) as it is a risk factor that can increase the risk of the serious side effect, Lactic Acidosis.


Q: What happens if I miss taking Bigomet?

Standard patient advice found in product information suggests that if a dose is missed, it should be taken as soon as possible. However, if it is almost time for the next scheduled dose, the missed dose should be skipped entirely, and the regular schedule resumed. Doses should not be doubled.


Q: What are the symptoms of Lactic Acidosis related to Bigomet?

Lactic Acidosis is a rare, life-threatening side effect. Official warnings list potential symptoms that may be subtle, including unusual muscle pain, severe sleepiness, slow or difficult breathing, abdominal discomfort, and a general feeling of malaise or weakness.


Q: Does Bigomet interact with common pain relievers like ibuprofen?

The official documentation includes warnings regarding the use of the active ingredient with non-steroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen. Taking these together may increase the risk of developing Lactic Acidosis, especially in patients who already have reduced kidney function.


Q: How quickly does Bigomet start working to affect blood sugar levels?

Regulatory data indicates that control of blood sugar is often attained within a few days of starting treatment. However, a final assessment of the overall drug response is typically not made before the 21st day of treatment or dose adjustment.


Q: Is it necessary to change my diet while taking Bigomet?

The active ingredient is formally indicated as an adjunct to diet and exercise to improve blood sugar control. Therefore, it is intended to be used alongside lifestyle changes.


Q: Are there any specific foods that should be avoided when taking Bigomet?

Official documentation stresses that all formulations should be taken with or immediately after meals to minimize gastrointestinal side effects. The specific dietary regimen should be determined as part of the overall management plan for diabetes.


Q: Is Bigomet considered a blood pressure medicine?

No, Bigomet is classified exclusively as a Biguanide derivative, which is an antihyperglycemic drug. Its primary purpose is to aid in the management of blood sugar levels in Type 2 Diabetes.


Q: Are there any long-term side effects associated with Bigomet use?

A documented potential long-term consequence of the active ingredient is the decreased absorption of Vitamin B12. This can lead to low serum levels and may require periodic testing and potentially B12 supplementation.


Q: Can Bigomet affect the results of lab tests?

Yes, regulatory information indicates that the active ingredient can potentially lower Vitamin B12 serum levels and affect hematological parameters (blood cell counts). This is why regular testing is required.


Q: Does Bigomet have an effect on cholesterol levels?

Official health bodies note that some studies have suggested the active ingredient may be associated with a reduction in LDL ('bad') cholesterol and total cholesterol levels, though this is not its primary approved function.


Q: Can taking Bigomet cause changes in mood or anxiety?

Official side effect documentation lists reports of neurological and psychiatric effects, including anxiety and nervousness. These are noted as less common or rare in clinical trials.


Q: How long does it take for Bigomet's full effect on A1C to be seen?

The effect of the active ingredient is progressive over time. Because of this, the time required for a full assessment of blood sugar control markers, such as HbA1c, is typically not determined until after 21 days of treatment or dose changes.


Q: Is there a maximum time someone can take Bigomet?

The active ingredient is formally indicated for the long-term management of Type 2 Diabetes Mellitus. No absolute maximum duration of use is defined in the official prescribing information.


Q: What are the general expectations for blood sugar reduction with Bigomet?

Clinical trials reviewed in regulatory documents demonstrate that the active ingredient is associated with a significant reduction in key blood sugar markers. These include Glycated Hemoglobin (HbA1c), Fasting Plasma Glucose (FPG), and Postprandial Glucose (PPG) levels.


Q: Can Bigomet interact with herbal supplements?

Official government health bodies note that there is not enough information to state that complementary or herbal remedies are safe to take with the active ingredient. This is because these products are not typically tested in the same way as prescription medicines.


Q: Why is Bigomet sometimes used in combination with other diabetes drugs?

The active ingredient is approved for use in combination with other antidiabetic agents, such as insulin and sulfonylureas. This approach is often used when glycemic control is inadequate with the active ingredient alone, as combination therapy has been shown to achieve a greater blood sugar reduction.


Q: Does the time of day matter when taking Bigomet?

The timing of intake is considered important, as all formulations are advised to be taken with or immediately after meals to support tolerability and absorption. The extended-release formulation is typically taken with the evening meal.


Q: Is Bigomet a sulfa drug?

No, Bigomet's active ingredient, Metformin, is classified as a Biguanide derivative. It is not chemically related to the sulfonylurea class of antidiabetic drugs, which are sometimes referred to as 'sulfa drugs'.


Q: Does the manufacturer of Bigomet provide specific warnings about driving or operating machinery?

Official warnings state that the active ingredient alone is not associated with hypoglycemia (low blood sugar). However, a risk of hypoglycemia is present when it is used in combination with other antidiabetic agents, which may impair the ability to drive or operate machinery.


Q: Can Bigomet be used by people who are not diabetic but have high blood sugar?

The active ingredient is officially indicated and approved as an adjunct to diet and exercise to improve glycemic control in people with Type 2 Diabetes Mellitus only. Use for other conditions is outside of the formal approved indications.


Q: What clinical research themes are commonly associated with Bigomet?

Beyond its primary indication, the active ingredient has been the subject of long-term research. Common research themes include investigating its potential influence on areas such as cardiovascular health and other age-related health markers.


Q: Is there any official information about stopping Bigomet suddenly?

The active ingredient is formally intended for long-term use. Official guidance primarily addresses temporary discontinuation prior to specific medical procedures, such as imaging using iodinated contrast agents or surgery.


Q: Does Bigomet affect fertility?

Official prescribing information advises premenopausal females of the potential for an unintended pregnancy with its use. This is due to the possibility that the restoration of ovulation may occur in some women.


Q: What are the signs of an allergic reaction to Bigomet?

While hypersensitivity is a contraindication, reported signs of an allergic reaction can include skin rash and hives (urticaria). In rare cases, more severe reactions may involve swelling of the face, lips, or tongue (angioedema).


Q: Is it true that Bigomet can reduce appetite?

Loss of appetite is explicitly listed as a very common side effect of the active ingredient. This effect is most often reported at the beginning of treatment.

How should Bigomet be stored and disposed of?

How to Store and Dispose of Bigomet?

Strict storage and disposal rules for Bigomet (metformin hydrochloride) are necessary to maintain its quality and ensure safety. Official regulations require storing the medicine at controlled room temperature, typically between 20 C and 25 C, allowing for brief excursions. It must be kept in the original container, with the lid tightly closed, to protect it from excessive heat, moisture, and light.

Safety and Disposal

To prevent accidental ingestion, the medication must be stored in a safe, locked location that is out of the sight and reach of children. When disposing of unused or expired Bigomet, follow local regulations. Do not flush the tablets down a toilet or pour them into a drain, as this prevents environmental contamination. Utilizing a drug take-back program or following specific instructions provided by a local regulatory body is the preferred disposal method.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Bigomet found in:

A-Z Index: